Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared some papers on LinkedIn:
“Hot off the press: delighted to share my commentary in JAMA Oncology an American Medical Association Journal
This piece reflects on Australia’s ‘Molecular Screening and Therapeutic’ (MoST) program and its landmark work in genomic therapy matching for patients with rare and refractory cancers.
My take: The MoST investigators have assembled a critical foundation for precision oncology’s future. Genomic profiling offers genuine hope for patients who have exhausted standard options, but transforming hope into extended survival means rigorously distinguishing genomic possibilities from validated therapeutic strategies.
The path forward requires:
- Platform trials testing ‘Rational Combination’ regimens
- Continuously updated, harmonized evidence frameworks to guide clinical decisions
- Reformed access policies that democratize precision oncology
MoST study provides the operational blueprint. The imperative now is generating tier-climbing evidence to fulfill the promise this field has made to patients. Let me know your thoughts.”
Title: Delivering Precision Oncology at Scale—Infrastructure, Evidence, and the Path Forward
Authors: Vivek Subbiah
Read the Full Article.
Title: Genomic Therapy Matching in Rare and Refractory Cancers
Authors: Frank Lin, Subotheni Thavaneswaran, John Grady
Read the Full Article.
Other articles featuring Vivek Subbiah on OncoDaily.